Advertisement

Lymph node cancer of the mediastinum with a putative necrotic primary lesion in the lung: a case report

  • Daichi Shikata
  • Takahiro Nakagomi
  • Rumi Higuchi
  • Yujiro Yokoyama
  • Toshio Oyama
  • Taichiro Goto
Open Access
Case Report
  • 384 Downloads

Abstract

Background

Although mediastinal lymph node cancer is presumed to originate in the lung, the primary site is usually unidentified, so the pathological course remains unclear. We recently encountered a case of mediastinal lymph node cancer having a putative primary lesion remaining in the lung as a necrotic focus.

Case presentation

The patient was a 56-year-old man who visited our department because computed tomography screening had revealed a nodular shadow in the lingular segment. However, on positron emission tomography, fluorine-18 deoxyglucose accumulation was detected in a subcarinal lymph node and not in the nodule in the lingular segment. Biopsy of the lung tumor and the lymph node was performed via minimal thoracotomy. Intraoperative pathologic examination showed necrosis alone and no malignant findings in the lung tumor. By contrast, carcinoma was detected in the lymph node. Additional subcarinal lymph node dissection was performed. Results of postoperative histopathologic examination indicated poorly differentiated adenocarcinoma of the subcarinal lymph node. Meanwhile, the nodule in the lingular segment was speculated to be a spontaneously resolved primary focus of lung cancer.

Conclusions

In this case, the primary lung cancer focus resolved spontaneously after lymph node metastasis, explaining the pathogenesis underlying mediastinal lymph node cancer of unknown primary site. For similar cases of malignancy, aggressive treatment, including surgery, is effective.

Keywords

Mediastinal cancer Lymph node cancer Unknown primary site Immunohistology Surgery 

Abbreviation

CEA

Carcinoembryonic antigen

CT

Computed tomography

CUP

Cancer of unknown primary site

FDG

Fluorine-18 deoxyglucose

Background

Cancer of unknown primary site (CUP) rarely occurs in the mediastinal lymph node, and its underlying pathology is typically not elucidated [1, 2]. Many cases of mediastinal lymph node cancer are presumed to arise from the lung, but the primary focus remains essentially unidentified at the time of diagnosis [1, 3, 4, 5]. Although patients are usually treated by chemoradiation therapy or surgery, no standard treatment has been established. We recently encountered a case of mediastinal lymph node cancer with a putative necrotic primary lesion in the lung.

Case presentation

The patient was a 56-year-old man in whom a nodular shadow was found in the left lower lung field via chest radiographic screening. Because close examination via computed tomography (CT) revealed a nodular shadow in the left lingular segment, the patient was referred to our department for surgery. He was an active smoker who consumed 1 pack/day for 30 years. No other noteworthy features were found in his past history or physical findings. The CT scan showed a 1-cm nodule in the left lingular segment (Fig. 1). However, positron emission tomography revealed fluorine-18 deoxyglucose (FDG) accumulation in the subcarinal lymph node and not in the nodular shadow in the lingular segment (Fig. 2a, b). FDG uptake was not noted in other organ lesions. Serum carcinoembryonic antigen (CEA) was elevated at 14.3 mg/ml (normal range 0.0–5.0 ng/ml). Biopsy of the lesions in the lung and the lymph node was performed for a definite diagnosis.
Fig. 1

Computed tomography. A small nodule was found in the lingular segment

Fig. 2

Positron emission tomography. a, b FDG uptake was detected in a subcarinal lymph node and not in a nodule in the lingular segment. The arrow indicates the lymph node with FDG accumulation

The patient underwent thoracoscopic surgery via two incisions by video-assisted thoracoscopic approaches: a 12-mm camera port incision was made at the eighth intercostal space, the posterior axillary line; and a 4-cm incision at the fourth intercostal space, the anterior axillary line. At the time of surgery, a 1-cm nodule was palpated in the lingular segment, and wedge resection at that site was performed. Intraoperative pathologic examination revealed inflammation and necrosis. The subcarinal lymph nodes were also resected and examined pathologically. Because the results indicated a cancer lesion, the remaining subcarinal and hilar lymph nodes were dissected. The patient was diagnosed with mediastinal lymph node cancer, and no additional lung resection, such as left upper lobectomy, was performed.

Histopathologic examination of the intrapulmonary nodule revealed necrosis and no viable tumor cells inside (Fig. 3a, b). Alveolar elastic fibers were well-maintained, and veins full of necrotic cells were observed (Fig. 3c, d). Granuloma was not evident, and acid-fast staining provided no evidence of acid-fast bacteria. Immunostaining showed irregular features positive for pan-cytokeratin (AE1/AE3) and napsin A in the necrotic tissue, suggesting residual cancer tissue (Fig. 4a, b). Meanwhile, a proliferation of large cancer cells with eosinophilic cytoplasm was found in the lymph node specimen (Fig. 5a, b). Cancer cells were found in the subcarinal lymph node, but not in additionally dissected regional lymph nodes. Immunostaining of the tumor cells was positive for pan-cytokeratin, TTF-1, and napsin A but negative for p40 and p63, suggesting a poorly differentiated adenocarcinoma of pulmonary origin (Fig. 5c, d).
Fig. 3

Histopathologic findings of the pulmonary nodule. a, b No viable cells could be observed inside the tumor (hematoxylin and eosin stain. a low magnification, b high magnification). c, d Vein filled with necrotic cells were observed (c hematoxylin and eosin stain; d Elastica van Gieson stain)

Fig. 4

Immunohistochemical findings of the pulmonary nodule. Immunostaining results of the necrotic tissue were positive for pan-cytokeratin (AE1/AE3) and napsin A (a pan-cytokeratin immunostaining; b napsin A immunostaining)

Fig. 5

Histopathologic findings of the subcarinal lymph node. a, b Solid proliferation of cancer cells was observed (hematoxylin and eosin stain. a low magnification, b high magnification). c, d Tumor cells were positive for pan-cytokeratin and napsin A (c pan-cytokeratin immunostaining; d napsin A)

The postoperative course was favorable, and the patient was discharged on the fifth postoperative day. Given that the cancer was at pTxN2M0 and stage IIIA according to lung cancer staging, concurrent chemoradiotherapy comprising systemic chemotherapy (cisplatin and vinorelbine) and radiotherapy of 60 Gy/30 Fr was administered. The serum CEA level reverted to normal after surgery (Fig. 6). To date, at 3 years after surgery, no recurrence has been noted.
Fig. 6

Time-course changes in the serum CEA level. The abscissa denotes time, and 1 scale corresponds to 1 month. Parallel dotted lines indicate omission of an intermediate step

Discussion

CUP is the collective term for a group of cancers for which the anatomical site of origin remains unidentified after a metastatic focus is found [6]. CUP is characterized by clinically unconfirmed primary malignancy, early occurrence of dissemination, rapid progression, and difficult prediction of the metastatic pattern [2, 6]. The incidence of CUP is reported to be approximately 0.5–6.7% [7, 8, 9, 10]. It occurs more frequently in men than in women, and most frequently involves the lymph nodes and bones [10]. Histologically, most cases are adenocarcinomas [10]. CUP rarely occurs in mediastinal lymph nodes, accounting for only 1.0–1.5% of all of the CUP cases [9, 10].

A possible pathogenesis of lymph node CUP is a small primary focus that cannot be detected with diagnostic imaging [3] or spontaneous resolution of the primary focus [10, 11]. Some immunologic mechanisms may be involved in the spontaneous resolution of the primary focus [11, 12]. Lymph node cancer of unknown primary origin possibly occurs if the primary focus is resolved spontaneously by host immunity, while a metastatic lymph node evades immune reactions. On the other hand, the lymph node itself may be the primary focus. In the latter case, malignant transformation of the ectopic epithelium in the lymph node may be responsible [10, 13, 14, 15]. However, all of these mechanisms are hypothetical and not based on scientific evidence.

In approximately 40% of reported cancers in the hilus, mediastinum, and cervical lymph nodes, the site of primary malignancy was the lung [10]. Taking into account the pathway of regional lymph flow in the lung, occult microcarcinoma can be considered to be present in the lung in cases of mediastinal lymph node CUP. Therefore, mediastinal lymph node cancer is commonly treated based on the assumption that the primary focus is lung cancer. In general, CUP prognosis is poor, with a median survival period of 2–9 months and a 5-year survival rate of 2.8–6.0% [2, 8]. Meanwhile, mediastinal lymph node CUP follows a clinical course different from that of CUP in general, and the prognosis is favorable when the localized focus in the lymph node is resected [3, 5, 16]. In cases of mediastinal lymph node enlargement, a surgical approach should be considered for both diagnostic and therapeutic purposes, even if the primary focus cannot be identified.

In our case, the mechanism of metastasis can be explained by lymphatic metastasis along the regional lymph flow, assuming that the primary focus was the nodule in the lingular segment and that the metastatic site was a subcarinal lymph node. The positive pan-cytokeratin and napsin A staining and the presence of necrotic cells in the blood vessels indicated the previous existence of cancer at that pulmonary site. There was no recurrence, including new primary lesions, during the 3-year follow-up after surgery noted in our patient. Thus, lymph node metastasis originating from lung cancer was highly probable based on the above reasons, although a definitive diagnosis is not possible. We believe that this case of mediastinal lymph node cancer exemplifies the hypothesis that a primary focus of lung cancer becomes necrotic through an immunologic mechanism during the clinical course, and a metastatic focus in the mediastinal lymph node alone survives and grows. Kohdono et al. reported a case of an increased metastatic focus in the mediastinal lymph node, with the primary lung cancer resolving spontaneously during the clinical course [4]. Although our present case resembles their case in some respects, to our knowledge, this is the first case of a pathologically verified etiologic mechanism of mediastinal lymph node cancer with the primary lesion remaining as necrotic tissue in the lung.

Recently published case reports regarding cancer of the intrathoracic lymph nodes were reviewed [3, 4, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25]. The patient characteristics of all 18 cases (including our case) are shown in Table 1. Fifteen patients were men and three were women; their average age was 63.5 years (range, 40–83 years). Except for one female patient, all patients were smokers. Seven patients had adenocarcinomas, six had squamous cell carcinomas, three had large cell carcinomas, and one had a small cell carcinoma. In 13 patients, certain tumor markers exceeded the normal range. The CUP was located in the lymph nodes of the mediastinum in 14 cases and in the pulmonary hilum in 4 cases. Surgery was performed in 13 patients, and adjuvant treatment after CUP resection consisted of radiation therapy in 4 cases, chemoradiation therapy in 3 cases, and no additional treatment in 6 cases. The outcomes after the treatment were as follows: 15 patients remained alive without recurrence or disease progression at an average of 28.8 months (range, 3–82 months), two patients remained alive with recurrence at an average of 66 months (6 and 126 months), and one patient died because of the disease 6 months after the treatment.
Table 1

Cancers of the intrathoracic lymph nodes with unknown primary site

Case

Author

Age (years)

Sex

Smoking history

Histology

Elevated TMs

Location

Treatment

Adjuvant treatment

Follow-up (months)

Outcome

1

Morita Y

56

Male

+

SQ

None

Med

LB and LND

None

20

Alive without recurrence

2

Kohdono S

67

Male

+

LA

None

Med

Tumor resection

RTx

6

Died of recurrence

3

Kohdono S

58

Female

+

LA

CEA

Med

LB and LND

RTx

6

Alive with recurrence

4

Kohdono S

56

Male

+

Small

SCC

rt. Hilum

LB and LND

None

16

Alive without recurrence

5

Blanco N

56

Male

+

SQ

no data

Med

Tumor resection

CRT

No data

Alive without recurrence

6

Kawasaki H

69

Male

No data

LA

CEA

rt. Hilum

LB and LND

None

20

Alive without recurrence

7

Tomita M

56

Male

+

SQ

SCC

lt. Hilum

Tumor resection

None

32

Alive without recurrence

8

Miwa K

72

Male

+

SQ

CEA

Med

LND

RTx

82

Alive without recurrence

9

Miwa K

78

Male

+

AD

CEA

Med

LND

RTx

44

Alive without recurrence

10

Miwa K

70

Male

+

SQ

None

Med

CRT

N/A

33

Alive without disease progression

11

Miwa K

76

Male

+

Undifferentiated

CEA

Med

CRT

N/A

24

Alive without disease progression

12

Shiota Y

69

Male

+

AD

CEA

Med

CRT

N/A

22

Alive without disease progression

13

Harada H

83

Female

No data

AD

NSE

Med

Tumor resection

None

38

Alive without recurrence

14

Watanabe N

55

Female

AD

CEA

Med

ALK-TKI

N/A

3

Alive without disease progression

15

Kim M.J.

59

Male

+

SQ

None

rt. Hilum

PN and LND

CRT

No data

Alive without recurrence

16

Kawasaki H

40

Male

+

AD

CEA

Med

LB and LND

None

126

Alive with recurrence

17

Yamasaki M

67

Male

+

AD

CEA

Med

EGFR-TKI

N/A

8

Alive without disease progression

18

Present case

56

Male

+

AD

CEA

Med

LND

CRT

32

Alive without recurrence

TM tumor marker, AD adenocarcinoma, SQ squamous cell carcinoma, LA large cell carcinoma, Undif undifferentiated carcinoma, SCC squamous cell carcinoma antigen, CEA carcinoembryonic antigen, NSE neuron-specific enolase, Med mediastinum, LB lobectomy, LND lymph node dissection, PN pneumonectomy, CRT chemoradiation therapy, ALK anaplastic lymphoma kinase, EGFR epidermal growth factor receptor, TKI tyrosine kinase inhibitor, RTx radiation therapy

Completely resected mediastinal lymph node CUP reportedly has a better prognosis than lung cancer with mediastinal lymph node metastasis [4, 10]. Complete resection is the first-line treatment if the lesion of the lymph node cancer of the hilum or mediastinum is localized [3, 5, 16]. Although the lung is highly likely to be the primary site of metastatic mediastinal lymph node cancer, lobectomy is generally avoided to preserve respiratory function. Even though chemoradiotherapy is often adopted as a postoperative treatment modality, there is no consensus on its therapeutic efficacy. In this case, postoperative chemoradiotherapy was performed at the request of the patient.

Conclusion

This case shows that lymph node CUP may occur due to the regression of the carcinoma itself at the primary site. As such, aggressive treatment, including surgical resection, should be performed for mediastinal lymph node CUP.

Notes

Acknowledgements

Not applicable.

Funding

No funding was received for this study.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors’ contributions

DS and TG wrote the manuscript. DS, TN, RH, YY, and TG performed the surgery. DS and TO performed the pathologic examination. TG was involved in the final editing of the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate

The study was approved by the institutional ethics board of Yamanashi Central Hospital.

Consent for publication

Written informed consent was obtained from the patient for publication of this case presentation and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.

Competing interests

The authors declare that they have no competing interests.

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

  1. 1.
    Izumi Y, Mukai M, Kikuchi K, Kobayashi K. Long-term survival after incomplete resection of immunohistochemically diagnosed T0N1 lung cancer: report of a case. Surg Today. 2006;36:270–3.CrossRefPubMedGoogle Scholar
  2. 2.
    Pavlidis N, Briasoulis E, Hainsworth J, Greco FA. Diagnostic and therapeutic management of cancer of an unknown primary. Eur J Cancer. 2003;39:1990–2005.CrossRefPubMedGoogle Scholar
  3. 3.
    Kawasaki H, Arakaki K, Taira N, Furugen T, Ichi T, Yohena T, Kawabata T. Lung cancer detected 5 years after resection of cancer of unknown primary in a mediastinal lymph node: a case report and review of relevant cases from the literature. Ann Thorac Cardiovasc Surg. 2016;22:116–21.CrossRefPubMedGoogle Scholar
  4. 4.
    Kohdono S, Ishida T, Fukuyama Y, Hamatake M, Takenoyama M, Tateishi M, Sugimachi K. Lymph node cancer of the mediastinal or hilar region with an unknown primary site. J Surg Oncol. 1995;58:196–200.CrossRefPubMedGoogle Scholar
  5. 5.
    Yoshizu A, Kamiya K. Mediastinal lymph node carcinoma of unknown primary site; report of a case. Kyobu Geka. 2012;65:507–9.PubMedGoogle Scholar
  6. 6.
    Briasoulis E, Pavlidis N. Cancer of unknown primary origin. Oncologist. 1997;2:142–52.PubMedGoogle Scholar
  7. 7.
    Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G, Group EGW. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22(Suppl 6):vi64–8.PubMedGoogle Scholar
  8. 8.
    Greco FA, Burris HA 3rd, Erland JB, Gray JR, Kalman LA, Schreeder MT, Hainsworth JD. Carcinoma of unknown primary site. Cancer. 2000;89:2655–60.CrossRefPubMedGoogle Scholar
  9. 9.
    Holmes FF, Fouts TL. Metastatic cancer of unknown primary site. Cancer. 1970;26:816–20.CrossRefPubMedGoogle Scholar
  10. 10.
    Riquet M, Badoual C, le Pimpec BF, Dujon A, Danel C. Metastatic thoracic lymph node carcinoma with unknown primary site. Ann Thorac Surg. 2003;75:244–9.CrossRefPubMedGoogle Scholar
  11. 11.
    Cafferata MA, Chiaramondia M, Monetti F, Ardizzoni A. Complete spontaneous remission of non-small-cell lung cancer: a case report. Lung Cancer. 2004;45:263–6.CrossRefPubMedGoogle Scholar
  12. 12.
    So T, Takenoyama M, Ichiki Y, Mizukami M, So T, Hanagiri T, Sugio K, Yasumoto K. A different pattern of cytotoxic T lymphocyte recognition against primary and metastatic tumor cells in a patient with nonsmall cell lung carcinoma. Cancer. 2005;103:200–8.CrossRefPubMedGoogle Scholar
  13. 13.
    Fellegara G, Carcangiu ML, Rosai J. Benign epithelial inclusions in axillary lymph nodes: report of 18 cases and review of the literature. Am J Surg Pathol. 2011;35:1123–33.CrossRefPubMedGoogle Scholar
  14. 14.
    Gould VE, Warren WH, Faber LP, Kuhn C, Franke WW. Malignant cells of epithelial phenotype limited to thoracic lymph nodes. Eur J Cancer. 1990;26:1121–6.CrossRefPubMedGoogle Scholar
  15. 15.
    Ishimaru Y, Shibata Y, Ohkawara S, Ohshima H, Kihara S. Lymphoepithelial cystic lesion related to adenocarcinoma in the mediastinum. Am J Clin Pathol. 1989;92:808–13.CrossRefPubMedGoogle Scholar
  16. 16.
    Harada H, Yamashita Y, Kuraoka K, Taniyama K. Sequential mediastinal lymphadenectomy of an unknown primary tumor. Ann Thorac Surg. 2013;95:687–9.CrossRefPubMedGoogle Scholar
  17. 17.
    Blanco N, Kirgan DM, Little AG. Metastatic squamous cell carcinoma of the mediastinum with unknown primary tumor. Chest. 1998;114:938–40.CrossRefPubMedGoogle Scholar
  18. 18.
    Kawasaki H, Yoshida J, Yokose T, Suzuki K, Nagai K, Hojo F, Kodama T, Nishiwaki Y. Primary unknown cancer in pulmonary hilar lymph node with spontaneous transient regression: report of a case. Jpn J Clin Oncol. 1998;28:405–9.CrossRefPubMedGoogle Scholar
  19. 19.
    Kim MJ, Lim SH, Han SJ, Choi KH, Lee SH, Park MW, Kang H, Na JO. Indolent metastatic squamous cell carcinoma of unknown primary in the intrathoracic lymph node: a case report and review of the literatures. Tuberc Respir Dis (Seoul). 2015;78:23–6.CrossRefGoogle Scholar
  20. 20.
    Miwa K, Fujioka S, Adachi Y, Haruki T, Taniguchi Y, Nakamura H. Mediastinal lymph node carcinoma of an unknown primary site: clinicopathological examination. Gen Thorac Cardiovasc Surg. 2009;57:239–43.CrossRefPubMedGoogle Scholar
  21. 21.
    Morita Y, Yamagishi M, Shijubo N, Nakata H, Kurihara M, Asakawa M. Squamous cell carcinoma of unknown origin in middle mediastinum. Respiration. 1992;59:344–6.CrossRefPubMedGoogle Scholar
  22. 22.
    Shiota Y, Imai S, Sasaki N, Tahara K, Noma B, Horita N, Taniguchi A, Ono T. A case of mediastinal lymph node carcinoma of unknown primary site treated with docetaxel and cisplatin with concurrent thoracic radiation therapy. Acta Med Okayama. 2011;65:407–11.PubMedGoogle Scholar
  23. 23.
    Tomita M, Matsuzaki Y, Shimizu T, Hara M, Ayabe T, Enomoto Y, Onitsuka T. Squamous cell carcinoma of the hilar lymph node with unknown primary tumor: a case report. Ann Thorac Cardiovasc Surg. 2008;14:242–5.PubMedGoogle Scholar
  24. 24.
    Watanabe N, Ishii T, Takahama T, Tadokoro A, Kanaji N, Dobashi H, Bandoh S. Anaplastic lymphoma kinase gene analysis as a useful tool for identifying primary unknown metastatic lung adenocarcinoma. Intern Med. 2014;53:2711–5.CrossRefPubMedGoogle Scholar
  25. 25.
    Yamasaki M, Funaishi K, Saito N, Sakano A, Fujihara M, Daido W, Ishiyama S, Deguchi N, Taniwaki M, Ohashi N, Hattori N. Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: a case report. Medicine (Baltimore). 2018;97:e9942.CrossRefGoogle Scholar

Copyright information

© The Author(s). 2018

Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Department of General Thoracic SurgeryYamanashi Central HospitalYamanashiJapan
  2. 2.Department of PathologyYamanashi Central HospitalYamanashiJapan

Personalised recommendations